# Sequential Vaccinations in Prostate Cancer Patients

> **NCT00060528** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Recombinant Fowlpox-GM-CSF
- **DRUG:** Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
- **DRUG:** Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)
- **DRUG:** Recombinant Human GM-CSF

## Key facts

- **NCT ID:** NCT00060528
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-22
- **Primary completion:** 2006-03-07
- **Final completion:** 2009-06-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060528, "Sequential Vaccinations in Prostate Cancer Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00060528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*